Likelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Recurrent Glioblastoma Multiforme (GBM)
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Relatlimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details:
Relatlimab (BMS-986016) is under development for the treatment of hematological malignancies, renal medullary carcinoma (RMC), newly diagnosed older acute myeloid leukemia, metastatic hepatocellular carcinoma (HCC), advanced unresectable or metastatic basal cell carcinoma, relapsed and refractory acute myeloid leukemia, non-Hodgkin lymphoma, relapsed refractory multiple myeloma, Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia (CLL), melanoma, metastatic uveal melanoma, multiple myeloma, gastric cancer, soft tissue sarcoma recurrent head and neck squamous cell carcinoma, non-small cell lung cancer, cervical cancer, ovarian cancer, bladder cancer, renal cell carcinoma, hepatocellular cancer, recurrent glioblastoma multiforme, gliosarcoma, colorectal cancer (solid tumors) and metastatic or unresectable melanoma (first line therapy). It is administered intravenously. It is a monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. It was under development for solid tumors in Japan.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas | |||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Primary Immune Deficiency (PID) reports